Defective genes account for∼ 80% of the total of more than 7,000 diseases known to date.
Gene therapy brings the promise of a one-time treatment option that will fix the errors in …

Gene vectors are nucleic acids that carry genetic materials or gene editing devices into cells
to exert the sustained production of therapeutic proteins or to correct erroneous genes of the …

Abstract Extracellular vesicles (EVs) are 30–150 nm membrane-bound vesicles naturally
secreted by cells and play important roles in intercellular communication by delivering …

The underlying cause of cancer is genetic disruption, so gene editing technologies,
particularly CRISPR/Cas systems can be used to go against cancer. The field of gene …

Understanding the molecular basis of disease and the design of rationally designed
molecular therapies has been the holy grail in the management of human cancers. Gene …

Hepatocellular carcinoma (HCC) is the most common malignancy of hepatocytes accounting
for 75‑85% of primary hepatic carcinoma cases. Small extracellular vesicles (sEVs) …

Glioblastoma (GBM) is the most malignant form of all primary brain tumors, and it is
responsible for around 200,000 deaths each year worldwide. The standard therapy for GBM …

Over the past decade, in vivo gene replacement therapy has significantly advanced,
resulting in market approval of numerous therapeutics predominantly relying on adeno …

Since it has been reported that extracellular vesicles (EVs) carry cargo using cell-to-cell
comminication according to various in vivo situations, they are exprected to be applied as …

Extracellular vesicles (EVs) have been exploited as bio-inspired drug delivery systems
(DDS) in the biomedical field. EVs have more advantages than synthetic nanoparticles: they …